Biomarker Technologies Market to Reach $58.50 Bn, Globally, by 2026 at 13.2% CAGR, Says Allied Market Research

News provided by

Jun 19, 2019, 10:35 ET

PORTLAND, Oregon, June 19, 2019 /PRNewswire/ -- Allied Market Research recently published a report, titled, "Biomarker Technologies Market by Product (Consumables, and Instruments), Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunoassay, and Others), and Application (Drug Discovery, Diagnostics, and Personalized Medicine), and Indication (Cancer, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026." The report provides a detailed analysis of the market, including key winning strategies, industry drivers and restraints, market size & forecast, top investment pockets, competitive scenario, and wavering market trends. According to the report, the global biomarker technologies market was estimated at $21.59 billion in 2018 and is expected to hit $58.50 billion by 2026, registering a CAGR of 13.2% during the forecast period.

Rise in prevalence of various diseases, surge in R&D activities in healthcare coupled with increase in adoption of early toxicity testing, advantages offered by biomarker in drug development, and rapid escalation in genome mapping programs drive the growth of the global biomarker technologies market. On the other hand, high initial capital investments required for biomarker discovery and lack of awareness regarding the use of biomarker technologies check the market growth to some extent. However, high potential of the emerging economies is expected to create lucrative opportunities for the key players in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5293

The consumables segment to rule the roost-

Based on product, the consumables segment accounted for more than two-third of the total market segment in 2018 and is expected to maintain its dominance throughout the forecast period. This is attributed to the crucial role consumables play in biomarker testing. The instruments segment, on the other hand, is projected to grow at the fastest CAGR of 14.1% through 2019–2026.

The immunoassay segment to retain its top status during the study period-

Based on technology, the immunoassay segment contributed to nearly half of the total market share in 2018 and is anticipated to lead the trail during the estimated period. Rise in prevalence of various types of cancers such as breast cancer, prostate cancer and others has spurred the growth. At the same time, the next generation sequencing segment is predicted to cite the fastest CAGR of 15.1% till 2026.

North America to maintain its dominance through 2019–2026-

Based on geography, North America held more than two-fifth of the market share in 2018 and is anticipated to dominate during the period 2019–2026. Surge in R&D related to drug discovery, easy availability of instruments and consumables, availability of trained technicians, and high prevalence of diseases such as cancer and autoimmune diseases have augmented the growth. Simultaneously, the Asia-Pacific region would showcase the fastest CAGR of 14.8% till 2026.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/5293

Frontrunners in the industry-

The key market players analyzed in the global biomarker technologies market report include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Agilent Technologies, Inc., LI-COR, Inc., Merck KGAA, PerkinElmer Inc., QIAGEN, Shimadzu Corporation, and F. Hoffmann-La Roche AG. These market players have adhered to a number of strategies including partnership, expansion, collaboration, joint ventures, and others to enhance their stand in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Pharmacogenomics Market - Opportunity Analysis and Industry Forecast, 2017 – 2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com